Time course of organ and hematological response to complement blockage in transplant-associated thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation
In summary, eculizumab is a well-tolerated promising therapeutic intervention for TA-TMA, but more studies are needed to establish its timing and dosage regimen in TA-TMA.
Authors
- Ivan Moiseev (ORCID: https://orcid.org/0000-0002-4332-0114)
- Elena Morozova (ORCID: https://orcid.org/0000-0002-0125-864X)
- Julia Yu. Vlasova
- L. S. Zubarovskaya (ORCID: https://orcid.org/0000-0003-2594-7703)
- Alexander Kulagin (ORCID: https://orcid.org/0000-0002-9589-4136)
- О. В. Паина (ORCID: https://orcid.org/0000-0001-7263-4326)
- О. А. Слесарчук (ORCID: https://orcid.org/0000-0002-6007-3899)
- Oleg V. Goloshchapov (ORCID: https://orcid.org/0000-0002-0736-1269)
- Tatiana Rudakova (ORCID: https://orcid.org/0000-0002-4601-7495)
- Т. А. Быкова (ORCID: https://orcid.org/0000-0002-4456-2369)
- Marina Gorodnova
- Tatiana S. Schegoleva
Institutions
- First Pavlov State Medical University of St. Petersburg (RU)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-03-27
- DOI
- https://doi.org/10.3389/fmed.2025.1551066
- Citations
- 2
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.59